Federica F. O'Brien
Independent DirectorMs. Federica F. O’Brien, also known as Freddi, BA, CPA (inactive), has been Chief Financial Officer at ImmunoGenesis, Inc. since November 2021. She serves as Consulting Chief Financial Officer at Geneos Therapeutics Inc. Ms. O’Brien has been serving as a financial and business operations consultant to ImmunoGenesis since September 2020. Previously she served as Chief Financial Officer of Complexa Inc. from May 2015 to December 2017 and as Chief Financial Officer of Cerecor Inc. from April 2013 to May 2015. She served as Strategic Finance Consultant & Chief Financial Officer at Geneos Therapeutics, Inc since March 2021 and serves as consultant chief financial officer. She serves as Independent Director at MacroGenics, Inc. since February 2021. She has been the President of CFO’Brien Consulting, Limited Liability Company since January of 2018 providing strategic, operational and financial consulting and flexible time Chief Financial Officer services primarily for biotech companies. She was Independent Director of TELA Bio, Inc. since November 13, 2019 until June 9, 2026. She served as the Chief Financial Officer of Complexa, Inc. from May2015 to December 2017. Ms. O’Brien served as the Chief Financial Officer of Cerecor, Inc. from April 2013 to May 2015. She served as Acting Chief Financial Officer and Treasurer of Tucows Inc. since June 1998 and served as its Vice President since September 1999. She served as Vice President for Finance and Chief Financial Officer of Cardiokine, Inc. She served as the Chief Financial Officer of Infonautics, Inc. From January 2003 to April 2005, Ms. O’Brien was the Corporate Controller at Barrier Therapeutics, Inc. (BTRX). She served as the Chief Financial Officer and Chief Operating Officer at Cervilenz Inc. from June 2011 to April 2013. Previously, she served as a Business Assurance Manager of Coopers & Lybrand LLP. She joined Cardiokine in April 2005 and served as Chief Financial Officer from April 2005 to July 2009. She served as a Director of Life Sciences for McGladrey LLP from February 2010 to May 2011. She served as a Director at GT Biopharma Inc., since April 26, 2018 until July 2, 2018. From July 2009 through February 2010, Ms. O’Brien provided financial and strategic consulting services. She has financial experience including in life sciences and as a trusted strategic and financial advisor to the leadership teams of growing biopharmaceutical companies as well as serving as a board member. She has diverse financial experience working with emerging growth companies, as well as public companies, primarily in the pharmaceutical and technology industries. Her experience includes operational, merger and acquisitions, financing, initial public offerings, financial reporting and public company compliance. She was part of the working group which took Barrier public in May 2004. During 2001 and 2002, she provided strategic Chief Financial Officer support and guidance to growth companies holding Interim and part-time Chief Financial Officer positions at a number of early stage venture-backed companies. In 1996, Ms. O’Brien joined Infonautics, Inc. as the Director of Finance, following Infonautics’ initial public offering. From 1994 to 1996, she was a Business Assurance Manager of Coopers & Lybrand L.L.P. She raised capital, expanded the patent portfolio worldwide and was instrumental in obtaining CE marking and ISO 13485 certification for a women’s healthcare device. Ms. O’Brien received her B.A. in Accounting from Rutgers University in 1980 and is a Member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.
Positions
- Company NameMacroGenics, Inc.Stock CodeMGNXPositionIndependent DirectorColleagues
- EBEric Blasius RisserCEO, President & Director
- WKWilliam K. HeidenIndependent Chairman of the Board
- JKJames KarrelsSenior VP & CFO
- EBEzio BonviniSenior VP of Research & Chief Scientific Officer
- ALAraba Lamouse-SmithVice President of Technical Operations
- JSJeffrey Stuart PetersSenior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
- EMEdward M. HurwitzIndependent Director
- MCMeenu Chhabra KarsonIndependent Director
